Atrial Flutter Clinical Trial
Official title:
Ablation Index in Standard vs. High Power Radiofrequency Ablation for Typical Atrial Flutter: A Randomized Study (AITAF)
A randomized controlled trial will be conducted to evaluate the efficacy of Ablation Index-guided high power - short duration (HPSD) ablation compared to conventional power settings in Cavotricuspid Isthmus (CTI) dependent atrial flutter. Participants will be randomized to receive either AI-guided HPSD ablation at 50 Watts or conventional power settings at 30 Watts. Both arms will use the Carto 3D mapping system and the QDOT MICRO ablation catheter (Biosense Webster). An anatomically contiguous line will be created with <6mm inter-lesion distance. After a standardized wait time of 30 minutes, ablation success will be assessed. The primary outcome is total radiofrequency ablation time. Secondary outcomes include procedural time, fluoroscopy time, safety outcomes, and 3-month freedom from recurrence. It is our expectation that HPSD will result in a shorter primary outcome.
Title: A Randomized Trial of Ablation Index Guided High vs Standard Power Radiofrequency Ablation for Typical Atrial Flutter Design: Prospective, two-arm, single center, superiority study with comparison of standard 30W power settings vs 50W high power settings Purpose: To evaluate the superiority of high-power ablation settings over standard power settings in achieving block across the CTI for typical flutter Enrollment: A minimum of 25 subjects in each arm. Enrollment over a period of 12 months. Subjects: Subjects referred by a cardiac electrophysiologist for standalone radiofrequency ablation of typical atrial flutter Clinical site: Foothills Medical Center, University of Calgary, Calgary, Alberta, Canada Endpoints: Primary endpoint: total radiofrequency time per procedure Secondary endpoints: RF time to initial CTI block Total procedure time Time from procedure start to procedure end Incidence of early reconnections during wait period Incidence of dormant conduction during adenosine testing Total number of ablation lesions required to achieve durable CTI block Total analgesia and sedation usage, e.g. midazolam, fentanyl and propofol in mg and/or mL Post-procedure patient perception of a) pain and b) nausea on a scale of 1 (none) to 10 (maximum possible) Secondary safety endpoints: Steam pops Pericardial effusions Pericardial tamponade Secondary follow-up outcomes: The presence of durable CTI block if a subsequent EP study is performed within 3 months of the initial procedure (e.g. AF ablation) Recurrence of documented AFL within 3 months by available ECGs, telemetry, wearable monitors, or Holters Holter at 2 months for incidence and burden of atrial arrhythmias Materials: 3-D electro-anatomical mapping system: CARTO, Biosense Webster Diagnostic catheters: 20-pole halo catheter, 10 pole coronary sinus catheter Ablation catheter: QDOT MICRO, BiosenseWebster Sponsors: None, fellow initiated research Despite the existing observational data, there have been no randomized controlled trials (RCTs) investigating HPSD in CTI ablation to validate its effectiveness. Furthermore, the applicability of AI to CTI ablation has not been tested. It's important to note that CTI ablation, performed under conscious sedation, introduces respiratory movement, leading to increased CF variability, which may affect precise energy delivery. We propose conducting the first RCT, to our knowledge, investigating the use of High-Power Short-Duration Ablation (HPSD) in the treatment of CTI-dependent flutter. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
| Terminated |
NCT02317029 -
Comparison of Oxygen Interventions and Defibrillator Efficiency
|
N/A | |
| Recruiting |
NCT01563848 -
Cryoablation in Patients With Atrial Flutter
|
Phase 2 | |
| Completed |
NCT01229254 -
Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter
|
Phase 2 | |
| Completed |
NCT02065388 -
Pharmacogenetic Dosing of Warfarin
|
Phase 3 | |
| Completed |
NCT00839657 -
Clarification of Optimal Anticoagulation Through Genetics
|
Phase 3 | |
| Completed |
NCT00232232 -
Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia
|
Phase 4 | |
| Completed |
NCT04884100 -
enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening
|
N/A | |
| Completed |
NCT05468281 -
RAFF5 Proposal: Improve the Quality and Safety of Patients Seen in the Emergency Department for Acute Atrial Fibrillation and Flutter
|
||
| Completed |
NCT03627143 -
Decreasing Hospital Admissions From the ED for AAFF
|
N/A | |
| Completed |
NCT02917538 -
A Randomized Trial of Contact Force in Atrial Flutter Ablation
|
N/A | |
| Enrolling by invitation |
NCT05903313 -
A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
|
||
| Recruiting |
NCT05755074 -
Ablation of Typical Right Atrial Flutter
|
N/A | |
| Recruiting |
NCT05883631 -
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
|
N/A | |
| Recruiting |
NCT03272620 -
Atrial Fibrillation at the Viennese University Emergency Department
|
N/A | |
| Completed |
NCT02810938 -
MIFI Flutter Registry - Ablation of Atrial Flutter With IntellaTip Sensor Technology
|
||
| Recruiting |
NCT02591875 -
Atrial Flutter Ablation in a Real World Population
|
N/A | |
| Completed |
NCT01914497 -
Dipole Density Mapping of Typical Atrial Flutter
|
N/A | |
| Completed |
NCT02268799 -
High Sensitivity Troponin T Levels Following DC Cardioversion for Atrial Fibrillation / Atrial Flutter
|
N/A | |
| Active, not recruiting |
NCT01976507 -
Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
|
Phase 4 |